Gynecologic Organ Involvement During Radical Cystectomy for Bladder Cancer: Is It Time to Routinely Spare the Ovaries?

TitleGynecologic Organ Involvement During Radical Cystectomy for Bladder Cancer: Is It Time to Routinely Spare the Ovaries?
Publication TypeJournal Article
Year of Publication2019
AuthorsTaylor BL, Matrai CE, Smith AL, Ayangbesan A, Xia L, Golombos DM, Mosquera JMiguel, Nicolas J, Robinson BD, Scherr DS, Khani F
JournalClin Genitourin Cancer
Volume17
Issue1
Paginatione209-e215
Date Published2019 Feb
ISSN1938-0682
KeywordsAdenocarcinoma, Aged, Carcinoma, Small Cell, Carcinoma, Squamous Cell, Cystectomy, Female, Follow-Up Studies, Humans, Organ Sparing Treatments, Ovary, Prognosis, Retrospective Studies, Urinary Bladder Neoplasms
Abstract

PURPOSE: To determine a subset of women who could undergo ovary-sparing radical cystectomy (OSRC) for bladder cancer without compromising oncologic safety.

PATIENTS AND METHODS: A retrospective review was performed of 164 consecutive women who underwent cystectomy at a single tertiary-care center from 1997 to 2018. Clinicopathologic and preoperative radiographic data were reviewed. Univariable and multivariable logistic regression models adjusting for pathologic stage, lymphovascular invasion (LVI), and carcinomain-situ were performed to evaluate the risk of ovarian and reproductive organ (RO) involvement.

RESULTS: A total of 123 women with a median age of 71 years underwent radical cystectomy (RC) with removal of ROs for primary bladder cancer. Nineteen women (15%) had RO involvement by bladder cancer, and 5 of them (4%) were specifically found to have ovarian involvement. Patients with ovarian involvement of bladder cancer had more locally advanced disease (P = .01), LVI (P = .003) and positive margins (P = .003). On multivariable logistic regression, ≥ pT3 (odds ratio = 10.2; 95% confidence interval, 2.0-51.6; P = .005) and LVI (odds ratio = 3.9; 95% confidence interval, 1.1-14.2; P = .037) were associated with increased risk of RO involvement. Among 15 patients excluded for having a nonbladder primary malignancy, a third had RO involvement, and 2 (13%) had ovarian metastases. No women in our cohort had a primary ovarian malignancy detected at the time of RC.

CONCLUSION: Women with ovarian involvement by malignancy at the time of RC either had locally advanced disease with LVI or a non-bladder primary malignancy. The risk of incompletely resecting the primary malignancy would be rare if OSRC was performed on women with organ-confined (≤T2) urothelial carcinoma.

DOI10.1016/j.clgc.2018.10.009
Alternate JournalClin Genitourin Cancer
PubMed ID30470630
Related Faculty: 
Brian Robinson, M.D. Francesca Khani, M.D. Juan Miguel Mosquera, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700